Return to homepagePandemic Pact

In vitro Diagnostic Test for Severe Fever and Thrombocytopenia Syndrome

Grant number: 7747

Grant search

Key facts

  • Disease

    Severe Fever with Thrombocytopenia Syndrome

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $451,000

  • Funder

    RIGHT Foundation

  • Principal Investigator

    N/A

  • Research Location

    41

  • Lead Research Institution

    Boreda Biotech

  • Research Priority Alignment

    N/A

  • Research Category

    N/A

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SFTS is an emerging tick-borne viral disease, with approximately 14,000 cases reported across Asia as of 2018. Despite its emerging status, no treatments, vaccines, or testing is available for acute infection of this virus. The development of SFTS antigen detection rapid diagnostic test (RDT) with higher sensitivity and specificity will allow for its wider use and overcome the limitations of the current laboratory-based PCR testing. The availability of such antigen detecting point-of-care tests are crucial in managing the spread of emerging infectious diseases.